All In Biotech

Drug Trial Radar · NCT05476770

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Last checked: Nov 20, 2026Latest source record: Dec 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Nov 11, 2022

Primary completion

Nov 11, 2025

Study completion Nov 11, 2027

Sponsor

Lead sponsor
Therapeutic Advances in Childhood Leukemia ConsortiumAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells. The rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date. This trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy. The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients. About 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study.

Conditions

  • Hematologic Malignancy
  • AML
  • ALL
  • BPDCN
  • MDS
  • Lymphoblastic Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, T-Cell
  • Hodgkin Lymphoma
  • Mixed Phenotype Acute Leukemia
  • Acute Undifferentiated Leukemia

Interventions

  • TagraxofuspDrug

    Dose will be assigned at study entry. Give IV over 15 minutes.

  • FludarabineDrug

    30 mg/m\^2 will be given IV over 30 minutes on days 1-5. Infusion will start 30 minutes after start of tagraxofusp on days 4 and 5.

  • CytarabineDrug

    2000 mg/m2 intravenously will be given daily over 1-3 hours for 5 days on days 1 through 5. Infusion will begin 4 hours after start of fludarabine. Because of an increased risk of neurotoxicity, it is recommended that IT cytarabine be separated from high dose IV cytarabine administration by at least 24 hours on C1D1.

  • DexamethasoneDrug

    * 20 mg/m2/day divided BID (max 40 mg/day) given orally on days 1 through 5 and 15 through 19. The two doses should be separated by at least 8 hours. * Any oral formulation of dexamethasone is acceptable. * IV may be given if oral formulation is not tolerated

  • VincristineDrug

    * 1.5 mg/m2 (maximum dose 2 mg) given intravenously as an IV push over 1-5 minutes or infusion via minibag as per institutional policy on days 1, 8, 15, and 22. * Infusion will start 30 minutes after start of tagraxofusp on day 8.

  • AzacitidineDrug

    * 75 mg/m2 subcutaneously or intravenously will be given daily over 15 minutes for 5 days on days 1 through 5. * Azacitidine will be given 30-60 minutes before beginning the tagraxofusp infusion.

  • MethotrexateDrug

    Give intrathecally: * 8 mg for patients age 1-1.99 * 10 mg for patients age 2-2.99 * 12 mg for patients 3-8.99 years of age * 15 mg for patients ≥9 years of age

  • Cytarabine ITDrug

    Give intrathecally: * 30 mg for patients age 1-1.99 * 50 mg for patients age 2-2.99 * 70 mg for patients ≥3 years of age If given as part of Triple IT Therapy: AML Patients: Age 1-1.99 - 24 mg Age 2-2.99 - 30 mg Age ≥3 years of age - 36 mg AML Patients: Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age 3-8.99 - 24 mg Age ≥9 years of age - 30 mg

  • HydrocortisoneDrug

    Given intrathecally. AML Patients: Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg AML Patients: Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of dose limiting toxicity (DLT) during cycle 1 of therapyTime frame: At the end of Cycle 1 (21 days for Part 1, and 28 days for Part 2)

Locations

31 sites in 2 countries. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles

    Los Angeles, California · Recruiting

  • Children's Hospital Orange County

    Orange, California · Not yet recruiting

  • UCSF School of Medicine

    San Francisco, California · Recruiting

  • Children's Hospital Colorado

    Denver, Colorado · Recruiting

  • Children's National Medical Center

    Washington D.C., District of Columbia · Recruiting

  • University of Miami

    Miami, Florida · Not yet recruiting

  • Children's Healthcare of Atlanta, Emory University

    Atlanta, Georgia · Not yet recruiting

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • Riley Hospital for Children

    Indianapolis, Indiana · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Not yet recruiting

  • National Cancer Institute, Pediatric Oncology Branch

    Bethesda, Maryland · Not yet recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Not yet recruiting

  • C.S. Mott Children's Hospital

    Ann Arbor, Michigan · Recruiting

  • Children's Hospital and Clinics of Minnesota

    Minneapolis, Minnesota · Not yet recruiting

  • Children's Hospital New York-Presbyterian

    New York, New York · Not yet recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Carolina-Levine Children's Hospital

    Charlotte, North Carolina · Not yet recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • Rainbow Babies

    Cleveland, Ohio · Not yet recruiting

  • Nationwide Children's Hospital

    Columbus, Ohio · Not yet recruiting

  • Oregon Health & Science University

    Portland, Oregon · Not yet recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Not yet recruiting

  • St. Jude Children's Research Hospital

    Memphis, Tennessee · Not yet recruiting

  • University of Texas, Southwestern

    Dallas, Texas · Recruiting

  • Cook Children's Hospital

    Fort Worth, Texas · Recruiting

  • Texas Children's Hospital/Baylor College of Medicine

    Houston, Texas · Recruiting

  • Primary Children's Hospital

    Salt Lake City, Utah · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Not yet recruiting

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Sydney Children's Hospital

    Sydney, Australia · Not yet recruiting

  • Children's Hospital at Westmead

    Westmead, New South Wales, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.